Bio-Path Holdings ( (BPTH) ) has released a notification of late filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bio-Path Holdings, Inc. has filed a Form 12b-25 notifying investors of a delay in submitting its Form 10-Q (Quarter Report) for the quarter ended March 31, 2026. The company emphasizes this is a timing issue related to broader year-end reporting work, rather than a signal of regulatory noncompliance.
Management explains that it is still compiling information for its Form 10-K (Yearly Report) covering the year ended December 31, 2025, and some of this data has not yet been received. Because the quarterly numbers tie closely to the annual reporting process, the company needs more time to ensure the filings are accurate and complete.
Bio-Path states that the delayed Form 10-Q (Quarter Report) will be filed within the standard grace period allowed under SEC Rule 12b-25. Specifically, the company expects to submit the quarterly report no later than five calendar days after the original due date, signaling to investors that the delay should be short.
The company does not anticipate any significant change in results of operations compared with the same quarter of the prior year. Investors should note that this expectation is a forward-looking statement, meaning actual results could differ if new information emerges before the Form 10-Q (Quarter Report) is filed.
Bio-Path affirms that all other required SEC periodic reports over the past 12 months have been filed on time, underscoring its ongoing compliance focus. The notification is signed by Vikram Grover, who serves as both Chief Executive Officer and Chief Financial Officer, reinforcing executive accountability for the delayed filing and the company’s communication with shareholders.
The most recent analyst rating on (BPTH) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Bio-Path Holdings stock, see the BPTH Stock Forecast page.
Spark’s Take on BPTH Stock
According to Spark, TipRanks’ AI Analyst, BPTH is a Neutral.
The score is driven down primarily by weak financial performance (no revenue, ongoing losses/cash burn, and negative equity), followed by bearish technicals with the stock trading below all key moving averages and negative MACD. Valuation metrics provide limited support due to a negative P/E and no dividend yield data.
To see Spark’s full report on BPTH stock, click here.
More about Bio-Path Holdings
Average Trading Volume: 23,424
Technical Sentiment Signal: Sell
Current Market Cap: $268.6K
See more insights into BPTH stock on TipRanks’ Stock Analysis page.